Related Experiment Video
Updated: Aug 14, 2025
Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells
Published on: October 20, 2015
The future of patient-derived xenografts in prostate cancer research
Mitchell G Lawrence1,2,3,4,5, Renea A Taylor6,7,8,9,10, Georgia B Cuffe11
1Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australia. mitchell.lawrence@monash.edu.
Abstract:
Patient-derived xenografts (PDXs) are generated by engrafting human tumours into mice. Serially transplantable PDXs are used to study tumour biology and test therapeutics, linking the laboratory to the clinic. Although few prostate cancer PDXs are available in large repositories, over 330 prostate cancer PDXs have been established, spanning broad clinical stages, genotypes and phenotypes. Nevertheless, more PDXs are needed to reflect patient diversity, and to study new treatments and emerging mechanisms of resistance. We can maximize the use of PDXs by exchanging models and datasets, and by depositing PDXs into biorepositories, but we must address the impediments to accessing PDXs, such as institutional, ethical and legal agreements. Through collaboration, researchers will gain greater access to PDXs representing diverse features of prostate cancer.
Insights
Patient-derived xenografts (PDXs) enable crucial research in prostate cancer, from understanding tumor biology to testing new therapies. Increased collaboration and data sharing are vital to expand access to these valuable models for diverse patient representation.
Area of Science:
- Oncology
- Translational Research
- Biobanking
Background:
- Patient-derived xenografts (PDXs) are critical tools for preclinical cancer research, bridging laboratory findings with clinical applications.
- Prostate cancer research benefits significantly from PDXs, which model diverse tumor characteristics.
- Despite over 330 established prostate cancer PDXs, a need exists for greater diversity and accessibility.
Purpose of the Study:
- To highlight the importance of patient-derived xenografts (PDXs) in advancing prostate cancer research.
- To emphasize the need for increased diversity in available prostate cancer PDX models.
- To address challenges and propose solutions for enhancing PDX accessibility and utilization.
Main Methods:
- Review of established prostate cancer PDX models and their characteristics.
- Analysis of current limitations in PDX accessibility and repository limitations.
- Discussion of strategies for improved model exchange and data sharing.
Main Results:
- Over 330 prostate cancer PDXs have been developed, representing a wide range of clinical and genetic features.
- Current PDX repositories lack sufficient diversity to fully represent the prostate cancer patient population.
- Barriers to PDX access include institutional, ethical, and legal hurdles.
Conclusions:
- Expanding the diversity and accessibility of prostate cancer PDXs is essential for comprehensive research.
- Enhanced collaboration, data sharing, and deposition into biorepositories can maximize PDX utility.
- Overcoming access impediments is crucial for researchers to leverage PDXs for studying new treatments and resistance mechanisms.
More Related Videos
08:38Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia
Published on: August 28, 2013
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020